Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 4
Submit an article Journal homepage
439
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluations

Sapacitabine for cancer

Xiaojun LiuThe University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX, USA
,
Hagop KantarjianThe University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX, USA
&
William PlunkettThe University of Texas M.D. Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX, USA+1 713 792 3335; +1 713 794 4316; [email protected];The University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX, USA
Pages 541-555 | Published online: 14 Feb 2012

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sun Young Oh, Shafia Rahman & Joseph A. Sparano. (2021) Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opinion on Pharmacotherapy 22:8, pages 981-1003.
Read now

Articles from other publishers (16)

Zai-Qun Liu. (2024) Is it still worth renewing nucleoside anticancer drugs nowadays?. European Journal of Medicinal Chemistry 264, pages 115987.
Crossref
Daisy Yan, One Hyuk Ra & Bingfang Yan. (2021) The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Animal Diseases 1:1.
Crossref
Jinsha Liu, Priyanka Pandya & Sepideh Afshar. (2021) Therapeutic Advances in Oncology. International Journal of Molecular Sciences 22:4, pages 2008.
Crossref
Marc-Olivier Labbé, Laura Collins, Carole-Anne Lefebvre, Wael Maharsy, Janie Beauregard, Starr Dostie, Michel Prévost, Mona Nemer & Yvan Guindon. (2020) Identification of a C3′-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth. Bioorganic & Medicinal Chemistry Letters 30:6, pages 126983.
Crossref
Xiaojun Liu, Yingjun Jiang, Kei-ichi Takata, Billie Nowak, Chaomei Liu, Richard D. Wood, Walter N. Hittelman & William Plunkett. (2019) CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death. Molecular Cancer Therapeutics 18:12, pages 2283-2295.
Crossref
Shani Paluch-Shimon & Ella Evron. (2019) Targeting DNA repair in breast cancer. The Breast 47, pages 33-42.
Crossref
Shuang Guo, Mingshuo Xu, Qi Guo, Fuqiang Zhu, Xiangrui Jiang, Yuanchao Xie & Jingshan Shen. (2019) Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents. Bioorganic & Medicinal Chemistry 27:5, pages 748-759.
Crossref
Nikolaos Tsesmetzis, Cynthia Paulin, Sean Rudd & Nikolas Herold. (2018) Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers 10:7, pages 240.
Crossref
Xiaojun Liu, Yingjun Jiang, Billie Nowak, Bethany Qiang, Nancy Cheng, Yuling Chen & William Plunkett. (2017) Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemotherapy and Pharmacology 81:2, pages 255-267.
Crossref
Gordon M. Cragg & David J. Newman. 2018. Natural Products as Source of Molecules with Therapeutic Potential. Natural Products as Source of Molecules with Therapeutic Potential 309 331 .
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Tsung-Huei Lai, Brett Ewald, Alma Zecevic, Chaomei Liu, Melanie Sulda, Dimitrios Papaioannou, Ramiro Garzon, James S. Blachly, William Plunkett & Deepa Sampath. (2016) HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clinical Cancer Research 22:14, pages 3537-3549.
Crossref
Pradeepkumar L. Patel, Niki K. Rana, Mayurbhai R. Patel, Stephen D. Kozuch & David Sabatino. (2016) Nucleic Acid Bioconjugates in Cancer Detection and Therapy. ChemMedChem 11:3, pages 252-269.
Crossref
Harry P. Erba. (2015) Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leukemia Research 39:2, pages 183-191.
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs 23 79 .
Takahiro Yamauchi, Kanako Uzui, Rie Nishi, Hiroko Shigemi & Takanori Ueda. (2014) Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line. BMC Cancer 14:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.